{"id":5848,"date":"2022-11-26T06:00:00","date_gmt":"2022-11-26T06:00:00","guid":{"rendered":"http:\/\/wp.cov19longhaulfoundation.org\/?p=5848"},"modified":"2022-11-26T06:00:00","modified_gmt":"2022-11-26T06:00:00","slug":"facial-nerve-paralysis-and-covid%e2%80%9019-a-systematic-review","status":"publish","type":"post","link":"https:\/\/cov19longhaulfoundation.org\/?p=5848","title":{"rendered":"Facial Nerve Paralysis and\u00a0COVID\u201019: A Systematic Review"},"content":{"rendered":"\n

Authors: Amirpouyan Namavarian<\/a>, MD, 1 <\/sup>Anas Eid<\/a>, BMSc, 2 <\/sup>Hedyeh Ziai<\/a>, MD, 1 <\/sup>Emily YiQin Cheng<\/a>, BSc, 3 <\/sup>and Danny Enepekides<\/a>, MD, MSc, FRCSC Laryngoscope.<\/a> 2022 Aug 8 : 10.1002\/lary.30333. doi: 10.1002\/lary.30333<\/a><\/p>\n\n\n\n

Abstract<\/h2>\n\n\n\n

Objective<\/h3>\n\n\n\n

Several cases of facial nerve paralysis (FNP) post\u2010COVID\u201019 infection have been reported with varying presentations and management. This study aims to identify FNP clinical characteristics and recovery outcomes among patients acutely infected with COVID\u201019. We hypothesize that FNP is a potentially unique sequalae associated with COVID\u201019 infections.<\/p>\n\n\n\n

Methods<\/h3>\n\n\n\n

A systematic review of PubMed\u2010Medline, OVID Embase, and Web of Science databases from inception to November 2021 was conducted following the Preferred Reporting Items for Systematic Reviews and Meta\u2010Analyses guidelines.<\/p>\n\n\n\n

Results<\/h3>\n\n\n\n

This search identified 630 studies with 53 meeting inclusion criteria. This resulted in 72 patients, of which 30 (42%) were diagnosed with Guillain\u2010Barr\u00e9 Syndrome (GBS). Non\u2010GBS patients were on average younger (36 vs. 53\u2009years) and more likely to present with unilateral FNP (88%) compared to GBS patients who presented predominantly with bilateral FNP (74%). Among non\u2010GBS patients, majority (70%) of FNP presented a median of 8 [IQR 10] days after the onset of initial COVID\u201019 symptom(s). Treatment for non\u2010GBS patients consisted of steroids (60%), antivirals (29%), antibiotics (21%), and no treatment (21%). Complete FNP recovery in non\u2010GBS patients was achieved in 67% patients within a median of 11 [IQR 24] days.<\/p>\n\n\n\n

Conclusion<\/h3>\n\n\n\n

FNP is a possible presentation post COVID\u201019 infections, associated with both GBS and non\u2010GBS patients. Although no causation can be assumed, the clinical course of isolated FNP associated with COVID\u201019 raises the possibility of a unique presentation differing from Bell’s palsy, seen with higher proportion of patients developing bilateral FNP and a shorter duration to complete recovery. Laryngoscope<\/em>, 2022<\/p>\n\n\n\n

Keywords: <\/strong>Bell’s palsy, COVID\u201019, facial nerve, paralysis<\/p>\n\n\n\n

Go to:<\/a><\/p>\n\n\n\n

Abstract<\/h2>\n\n\n\n

Several cases of facial nerve paralysis (FNP) post\u2010COVID\u201019 infection have been reported. This study aims to identify FNP clinical characteristics and recovery outcomes among patients acutely infected with COVID\u201019. A systematic review of databases was performed resulting in 53 included studies and a total of 72 patients, of which 30 (42%) were diagnosed with Guillain\u2010Barr\u00e9 Syndrome (GBS). Among non\u2010GBS patients, 70% of FNP presented a median of 8\u2009days after the onset of initial COVID\u201019 symptom(s). Complete FNP recovery in non\u2010GBS patients was achieved in 67% patients within a median of 11\u2009days. Although no causation can be assumed, the clinical course of isolated FNP associated with COVID\u201019 raises the possibility of a unique presentation differing from Bell’s palsy, seen with higher proportion of patients developing bilateral FNP and a shorter duration to complete recovery.<\/p>\n\n\n\n

\"An<\/figure>\n\n\n\n

Go to:<\/a><\/p>\n\n\n\n

INTRODUCTION<\/h2>\n\n\n\n

Facial nerve paralysis\/palsy (FNP) is a debilitating condition with significant morbidity associated with functional and psychological implications. 1 <\/a>Although the etiology of FNP is broad, viral\u2010associated Bell’s palsy is thought to be the most prevalent contributor. 2 <\/a>Herpes simplex virus (HSV) and Varicella zoster virus (VZV) are known contributors in the development of Bell’s Palsy in the pediatric and adult population. 3 <\/a>, 4 <\/a>Since the onset of the COVID\u201019 pandemic, FNP incidence has increased and there has been a suggested association with COVID\u201019 infections. 5 <\/a>, 6 <\/a>, 7 <\/a>, 8<\/a><\/p>\n\n\n\n

Many neurological symptoms have been reported in patients infected with COVID\u201019 including anosmia, ageusia, myalgia, paraplegias, and facial palsy among others. 9 <\/a>, 10 <\/a>FNP has been described by numerous studies as an outcome of COVID\u201019, either as an isolated symptom in patients who have otherwise been asymptomatic or in combination with other COVID\u201019 symptoms. 6 <\/a>, 11 <\/a>Guillain\u2010Barr\u00e9 Syndrome (GBS), an autoimmune polyneuropathy, is linked to viral infections including Epstein\u2013Barr virus (EBV), VZV, human immunodeficiency virus, and influenza among others. 12 <\/a>GBS has also been described by numerous case reports as a sequelae of COVID\u201019 infections, with many reported cases of FNP. 13 <\/a>The mechanism of GBS is believed to involve an aberrant immune response resulting in nerve trauma secondary to inappropriate complement activation and inflammatory mediators. 14<\/a><\/p>\n\n\n\n

The current literature highlights facial paralysis in COVID\u201019 infected patients including both adult and pediatric cohorts. Although many case reports have described the presence of acute facial paralysis in COVID\u201019 patients, to date, there is no comprehensive systematic review on these patients. The objective of this study is to identify FNP clinical characteristics and recovery outcomes among patients acutely infected with COVID\u201019 (confirmed by a positive reverse transcription polymerase chain reaction [RT\u2010PCR]). We hypothesize that FNP is a potentially unique sequalae associated with COVID\u201019 infections. In this systematic review, we summarize the current literature on the presentations of facial nerve paralysis in COVID\u201019 patients and describe the management of these patients with the aim of providing guidance for future practitioners on these patients’ clinical diagnosis and management.<\/p>\n\n\n\n

Go to:<\/a><\/p>\n\n\n\n

METHODS<\/h2>\n\n\n\n

Search Strategy<\/h3>\n\n\n\n

This systematic review was completed using the Preferred Reporting Items for Systematic Reviews and Meta\u2010Analyses (PRISMA) guidelines (Fig. 1<\/a>). The search strategy was conducted using Ovid Embase, PubMed\u2010Medline, CINAHL and Web of Science databases from inception to November 2021. The database search was done by two reviewers (a.e.\/a.n.). Keywords and medical subject headings (MeSH) included facial, facial nerve, peripheral facial nerve, paralysis, paresis, palsy, droop, impair*, Bell’s palsy, weakness, disease, movement, COVID\u201019, coronavirus, covid, and SARS\u2010CoV\u20102. The exact search details used for all databases are found in Table S1<\/a>.<\/p>\n\n\n\n

<\/a><\/p>\n\n\n\n

\"An<\/a><\/figure>\n\n\n\n

Fig. 1<\/a><\/p>\n\n\n\n

PRISMA flow diagram. a<\/sup>Two studies were included after a screen of the citations from the papers during the eligibility phase. RT\u2010PCR = reverse transcription polymerase chain reaction. [Color figure can be viewed in the online issue, which is available at www.laryngoscope.com<\/a>.]<\/p>\n\n\n\n

Inclusion and Exclusion Criteria<\/h3>\n\n\n\n

Inclusion criteria consisted of studies reporting FNP in adult and\/or pediatric patients actively infected with COVID\u201019. This was defined as a positive COVID\u201019 RT\u2010PCR result. There was no comparator and the outcomes recorded included study design, patient demographic, and FNP clinical characteristics and recovery outcome. Published original studies including case reports, randomized controlled trials, prospective, or retrospective observational studies, cross\u2010sectional and case\u2013control trials since journal inception were included. Patients with non\u2010active COVID\u201019 infections (i.e., negative RT\u2010PCR results) despite positive serology (positive immunoglobulin G) were excluded. Furthermore, papers published in a non\u2010English language or non\u2010peer reviewed publications (abstracts, conference posters, reviews, letters to editors, and editorials) were also excluded.<\/p>\n\n\n\n

Data Extraction and Analysis<\/h3>\n\n\n\n

The search titles and abstracts were independently screened by two reviewers (a.e.\/a.n.) based on the inclusion and exclusion criteria. Complete manuscripts were retrieved and independently reviewed by the same two reviewers. If there were any disagreements in article selection between the two reviewers, these were resolved by consensus. If a disagreement persisted, a third reviewer was consulted (h.z.). All titles, abstracts, and full texts screening were completed using Covidence (version 1501). Cross\u2010checking of the included articles and relevant reviews, as well as a manual web search was conducted for unidentified articles. Extracted data included study design, study population demographics, and clinical characteristics. Information regarding FNP onset, laterality, House\u2010Brackmann (HB) score, associated symptoms, investigations, treatments, and outcomes was extracted. Patients in studies that did not report HB score were assigned a score by the reviewers based on the described clinical presentation and HB scale by the reviewers when possible. 15 <\/a>Similarly, if there was any disagreement between the two reviewers, a third reviewer was consulted.<\/p>\n\n\n\n

Risk of Bias Assessment<\/h3>\n\n\n\n

The Joanna Briggs Institute critical appraisal checklist for case reports and case series assessment tools were used to appraise the quality of the studies. This was independently assessed by two authors (a.e. and e.c.). Discrepancies were resolved by consensus or by involving a third author (a.n.). The quality of the studies was quantified according to the assessment tools and a final quality rating of \u201cGood,\u201d \u201cFair,\u201d or \u201cPoor\u201d was given (Table S2A and B<\/a>). For case reports, \u201cGood\u201d was defined as at least 6 out of 8 criteria met, \u201cFair\u201d as 4 or 5 criteria met, and \u201cPoor\u201d as 3 or less criteria met. For case series, \u201cGood\u201d was defined as at least 7 out of 10 criteria met, \u201cFair\u201d as 5 or 6 criteria met, and \u201cPoor\u201d as 4 or less criteria met.<\/p>\n\n\n\n

Statistical Analysis<\/h3>\n\n\n\n

Descriptive statistics were computed for all variables. Categorical variables were reported as unweighted frequencies and percentages. Continuous variables were reported as medians and interquartile range (IQR). Subgroup analysis was performed based on GBS status. IBM SPSS Statistics for Windows, Version 27.0 was used for all statistical analyses.<\/p>\n\n\n\n

Go to:<\/a><\/p>\n\n\n\n

RESULTS<\/h2>\n\n\n\n

Study Selection<\/h3>\n\n\n\n

Our search identified 1064 studies. After duplicates were removed, a total of 630 studies were reviewed for initial screening. Fifty\u2010two studies met our inclusion, and two studies were found during our screen of citations listed in our included papers. A total of 54 studies were included (Fig. 1<\/a>), resulting in 73 patients. 5 <\/a>, 6 <\/a>, 7 <\/a>, 9 <\/a>, 10 <\/a>, 11 <\/a>, 16 <\/a>, 17 <\/a>, 18 <\/a>, 19 <\/a>, 20 <\/a>, 21 <\/a>, 22 <\/a>, 23 <\/a>, 24 <\/a>, 25 <\/a>, 26 <\/a>, 27 <\/a>, 28 <\/a>, 29 <\/a>, 30 <\/a>, 31 <\/a>, 32 <\/a>, 33 <\/a>, 34 <\/a>, 35 <\/a>, 36 <\/a>, 37 <\/a>, 38 <\/a>, 39 <\/a>, 40 <\/a>, 41 <\/a>, 42 <\/a>, 43 <\/a>, 44 <\/a>, 45 <\/a>, 46 <\/a>, 47 <\/a>, 48 <\/a>, 49 <\/a>, 50 <\/a>, 51 <\/a>, 52 <\/a>, 53 <\/a>, 54 <\/a>, 55 <\/a>, 56 <\/a>, 57 <\/a>, 58 <\/a>, 59 <\/a>, 60 <\/a>, 61 <\/a>, 62 <\/a>, 63 <\/a>The characteristics of each study can be found in Table S3<\/a>.<\/p>\n\n\n\n

Clinical Features: Non\u2010GBS Versus GBS Patients<\/h3>\n\n\n\n

The clinical presentations are summarized in Table I<\/a>. Forty\u2010two percent of patients presented with FNP in the context of GBS. Patients without GBS were younger than those with GBS (36 vs. 54\u2009years, respectively). Additionally, more non\u2010GBS patients presented with unilateral FNP compared to those with GBS (88% vs. 26%, respectively). Furthermore, non\u2010GBS patients had a shorter delay to FNP onset (median [IQR]; 8 [10] days) from the onset of initial COVID\u201019 symptoms compared to GBS patients (16 [11] days).<\/p>\n\n\n\n

TABLE I<\/h3>\n\n\n\n

Overall Study Demographics and FNP Clinical Presentations.<\/p>\n\n\n\n

<\/th>Non\u2010GBS (n<\/em> = 42)<\/th>GBS (n<\/em> = 30)<\/th><\/tr><\/thead>
Patients (%)<\/td>58<\/td>42<\/td><\/tr>
Age (years), median [IQR]<\/td>36 [22]<\/td>54 [23]<\/td><\/tr>
Male, n<\/em> (%)<\/td>19 (49)<\/td>21 (70)<\/td><\/tr>
Onset of FNP relative to COVID\u201019 symptoms, n<\/em> (%)<\/td><\/tr>
Only FNP<\/td>4 (11)<\/td>0<\/td><\/tr>
Before or concurrent<\/td>7 (19)<\/td>2 (6.8)<\/td><\/tr>
After<\/td>26 (70)<\/td>27 (93.1)<\/td><\/tr>
Days from initial symptoms to onset of FNP, median [IQR]<\/td>8 [10]<\/td>16 [11]<\/td><\/tr>
Unilateral FNP, n<\/em> (%)<\/td>37 (88)<\/td>7 (25.9)<\/td><\/tr>
Degree of FNP, median [IQR]<\/td>3 [2]<\/td>4.5 [3]<\/td><\/tr>
Complete recovery of FNP achieved, n<\/em> (%)<\/td>20 (67)<\/td>4 (13.3)<\/td><\/tr>
Days to complete recovery of FNP, median<\/td>11 [24]<\/td>30<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Open in a separate window<\/a><\/p>\n\n\n\n

FNP = facial nerve paralysis; GBS = Guillain\u2010Barr\u00e9 Syndrome; IQR = interquartile range.<\/p>\n\n\n\n

Thirty\u2010two studies reported the severity of the FNP using the House\u2010Brackmann scale, the median grade was 3 [IQR 2] and 4.5 [3] for non\u2010GBS and GBS patients, respectively.<\/p>\n\n\n\n

Of the COVID\u201019 symptoms, the most reported were fever (36% and 60% in non\u2010GBS and GBS patients, respectively) and cough (32% and 63% in non\u2010GBS and GBS patients, respectively). When considering neurological symptoms in patients with COVID\u201019 other than FNP, impairments in taste function (e.g., ageusia, hypogeusia or dysgeusia) were most reported (10% in non\u2010GBS vs. 37% in GBS) followed by impairments in olfaction (8% and 23% in non\u2010GBS and GBS patients, respectively). The detailed distribution of symptoms associated with COVID\u201019 is found in Table II<\/a>.<\/p>\n\n\n\n

TABLE II<\/h3>\n\n\n\n

Patient Symptoms.<\/p>\n\n\n\n

Symptom<\/th>Non\u2010GBS (n<\/em> = 42), n<\/em> (%)<\/th>GBS (n<\/em> = 30), n<\/em> (%)<\/th><\/tr><\/thead>
Non\u2010neurologic<\/td><\/tr>
Fever<\/td>10 (36)<\/td>18 (60)<\/td><\/tr>
Cough<\/td>9 (32)<\/td>19 (63.3)<\/td><\/tr>
Myalgia<\/td>8 (29)<\/td>5 (16.7)<\/td><\/tr>
Dyspnea<\/td>5 (18)<\/td>7 (23.3)<\/td><\/tr>
Fatigue<\/td>3 (11)<\/td>5 (16.7)<\/td><\/tr>
Neurologic<\/td><\/tr>
Anosmia or hyposmia<\/td>3 (8)<\/td>7 (23.3)<\/td><\/tr>
Ageusia, hypogeusia, dysgeusia<\/td>4 (10)<\/td>11 (36.7)<\/td><\/tr>
Dysarthria<\/td>0<\/td>4 (13.3)<\/td><\/tr>
Dysphagia<\/td>0<\/td>4 (13.3)<\/td><\/tr>
Odynophagia<\/td>1 (3)<\/td>1 (3.3)<\/td><\/tr>
Diplopia<\/td>1 (3)<\/td>3 (10)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Open in a separate window<\/a><\/p>\n\n\n\n

GBS = Guillain\u2010Barr\u00e9 Syndrome.<\/p>\n\n\n\n

When considering the distribution of non\u2010neurological COVID\u201019 symptoms based on patient GBS status, more GBS patients presented with a cough compared to non\u2010GBS patients (63% vs. 32%, respectively) (Table II<\/a>). More GBS presented with taste dysfunction (37% vs. 10%), dysarthria (13% vs. 0%), and dysphagia (13% vs. 0%) compared with non\u2010GBS patients.<\/p>\n\n\n\n

Imaging<\/h3>\n\n\n\n

The distribution of utilized imaging investigations is shown in Table S3<\/a>. Magnetic resonance imaging was performed in 36 patients, all of which reported no structural pathology contributing to their FNP (i.e., retro cochlear or middle ear pathology).<\/p>\n\n\n\n

Treatment<\/h3>\n\n\n\n

A summary of the management is shown in Table III<\/a>. The non\u2010GBS patients were most frequently treated with steroids (n<\/em> = 25, 60%), followed by antivirals (n<\/em> = 12, 29%), antibiotics (n<\/em> = 9, 21%), symptom management\/no treatment (n<\/em> = 9, 21%), intravenous immunoglobulins (IVIG) (n<\/em> = 4, 10%), hydroxychloroquine (n<\/em> = 4, 10%), and physiotherapy (n<\/em> = 2, 5%). On the other hand, patients with GBS were most treated with IVIG (n<\/em> = 24, 80%), followed by hydroxychloroquine (n<\/em> = 12, 43%), plasmapheresis (n<\/em> = 8, 27%), steroids (n<\/em> = 7, 23%), antivirals (n<\/em> = 6, 21%), antibiotics (n<\/em> = 6, 21%), and physiotherapy (n<\/em> = 1, 3%).<\/p>\n\n\n\n

TABLE III<\/h3>\n\n\n\n

Patient Management.<\/p>\n\n\n\n

Treatment<\/th>Non\u2010GBS (%)<\/th>GBS (%)<\/th><\/tr><\/thead>
Steroids<\/td>25 (60)<\/td>7 (23.3)<\/td><\/tr>
Antivirals<\/td>12 (29)<\/td>6 (21.4)<\/td><\/tr>
Antibiotics<\/td>9 (21)<\/td>6 (21.4)<\/td><\/tr>
Hydroxychloroquine<\/td>4 (10)<\/td>12 (42.9)<\/td><\/tr>
IVIG<\/td>4 (10)<\/td>24 (80)<\/td><\/tr>
Plasmapheresis<\/td>0<\/td>8 (26.7)<\/td><\/tr>
Physiotherapy<\/td>2 (5)<\/td>1 (3.3)<\/td><\/tr>
No treatment<\/td>9 (21)<\/td>0<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Open in a separate window<\/a><\/p>\n\n\n\n

GBS = Guillain\u2010Barr\u00e9 Syndrome; IVIG = intravenous immunoglobulins.<\/p>\n\n\n\n

Recovery Outcomes: Non\u2010GBS Versus GBS<\/h3>\n\n\n\n

More patients presenting without GBS had complete recovery of their FNP symptoms compared to those with GBS (67% vs. 13% respectively; Table I<\/a>). Among those with complete recovery in the non\u2010GBS group, the majority (80%) did not have any additional neurological symptoms, whereas a minority (20%) had further cranial nerve involvement. Fifty\u2010three percent (n<\/em> = 8) of those 15 patients treated with steroids in the non\u2010GBS group completely recovered within 60\u2009days. In contrast, only 15% (n<\/em> = 2\/13) of the GBS patients treated with IVIG achieved complete FNP recovery within 44\u2009days. There was insufficient data on steroid therapy among GBS patients to compare outcomes to non\u2010GBS patients.<\/p>\n\n\n\n

Go to:<\/a><\/p>\n\n\n\n

DISCUSSION<\/h2>\n\n\n\n

This systematic review summarizes FNP in the context of COVID\u201019 infections highlighting patients with systemic autoimmune pathology of GBS and isolated FNP (non\u2010GBS). Most patients had moderate FNP as graded on the HB scale. Of the reported non\u2010neurological COVID\u201019 symptoms, the most common were fever and cough. Patients with and without GBS during COVID\u201019 infections presented and progressed with FNP differently, with GBS patients typically presenting with a delayed onset, more severe FNP, and worse facial nerve outcomes. Additionally, the clinical course of isolated FNP associated with COVID\u201019 appears to differ from typical Bell’s palsy. Non\u2010GBS FNP patients had a shorter duration to complete recovery and a higher proportion of bilateral FNP compared to Bell’s palsy patients. This suggests that we may be observing an etiology different than Bell’s palsy patients with differing presentation and prognosis.<\/p>\n\n\n\n

Patients diagnosed with GBS were on average older than non\u2010GBS patients and the duration from the onset of COVID\u201019 symptoms to the manifestation of FNP differed considerably between the GBS and non\u2010GBS diagnosed subgroups. The most common treatments for non\u2010GBS patients consisted of steroids, antivirals, and antibiotics. Complete recovery of FNP in non\u2010GBS patients was achieved in over two thirds of patients within an average of under 3\u2009weeks. In contrast, only 17% of GBS patients achieved complete recovery of FNP within an average of over a month.<\/p>\n\n\n\n

Clinical Presentation<\/h3>\n\n\n\n

The initial COVID\u201019 symptoms including cough, fever, and dyspnea can be challenging to interpret as they are similar to common upper respiratory tract infections. With the advent of COVID\u201019, clinical suspicion of these symptoms has become increasingly recognized and should also be considered when taking a history from a patient presenting with acute FNP. In the context of known viral etiologies related to FNP, COVID\u201019 infected patients presented differently. For example, when evaluating the non\u2010GBS patient category, most patients with FNP after COVID\u201019 infection (70%) presented on average 9\u2009days (1\u201320\u2009days) after the onset of initial COVID\u201019 symptom(s). In comparison, FNP secondary to Ramsay Hunt syndrome typically presents either before or concurrently with the typical manifestations including VZV blisters. 64 <\/a>, 65<\/a><\/p>\n\n\n\n

In terms of laterality, bilateral FNP is an extremely rare clinical manifestation of Bell’s palsy, accounting for only up to 2% of these patients. 66 <\/a>, 67 <\/a>, 68 <\/a>, 69 <\/a>In comparison, a larger proportion (12%) of the isolated FNP patients in this review presented with bilateral FNP. This may be explained by the potentially greater inflammatory impact of the COVID\u201019 virus on the facial nerve that has been previously hypothesized. 6 <\/a>In our study, approximately 75% of the GBS patients presented with bilateral FNP which was higher than non\u2010GBS patients. Unlike Bell’s palsy, GBS has systemic involvement, more severe symptoms, and highly variable clinical course and outcome. 70<\/a><\/p>\n\n\n\n

Lastly, a small minority (11%) of the non\u2010GBS patients presented with FNP as either their presenting or sole symptom of COVID\u201019 during an active infection. These findings highlight the importance of considering COVID\u201019 infection in the differential diagnosis when evaluating patients with isolated FNP symptoms who may otherwise be asymptomatic. An RT\u2010PCR for COVID\u201019 may be considered in an infectious work\u2010up of patients presenting with isolated FNP.<\/p>\n\n\n\n

Treatments and Outcomes<\/h3>\n\n\n\n

The most common treatment for non\u2010GBS patients consisted of steroids, antivirals, and\/or antibiotics. Twenty percent of patients had no treatment. According to the American Academy of Neurology (AAN) and the American Academy of Otolaryngology\u2010Head and Neck Surgery Foundation (AAO\u2010HNSF), the treatment of Bell’s palsy primarily focuses on the use of corticosteroids and advises against the routine use of antiviral therapy. 71 <\/a>, 72 <\/a>, 73 <\/a>However, previous studies have shown that treatment of FNP from Bell’s palsy and RHS with acyclovir and prednisone leads to better outcomes. 74 <\/a>, 75 <\/a>Half of those treated with steroids and half of patients treated with antiviral therapy had complete recovery within 60\u2009days. Among our non\u2010GBS patients, there were no differences in outcomes between prednisone monotherapy and the combination therapy with antivirals.<\/p>\n\n\n\n

Our findings suggest that patients with GBS who develop FNP were more likely to develop severe presentations and were more prone to worse clinical outcomes. Patients presenting with FNP in the context of GBS were most treated with IVIG, followed by hydroxychloroquine, plasmapheresis, and\/or steroids. The first line treatments for GBS are plasma exchange or IVIG therapy which should be initiated within 7 and 14\u2009days of symptom onset, respectively, to hasten recovery. 76 <\/a>In contrast, corticosteroids are not recommended for the treatment of GBS, as several clinical trials have shown no benefit in recovery outcomes compared to placebo. 77 <\/a>This could explain why steroids were much less commonly used in our GBS patients compared to plasmapheresis and IVIG. Importantly, patients presenting with GBS and FNP were over three times less likely to have complete recovery of FNP compared to non\u2010GBS patients. This can be explained by the systemic involvement of GBS with more severe symptoms, and highly variable clinical course and outcome. 70<\/a><\/p>\n\n\n\n

When comparing patients with Bell’s palsy, FNP associated with COVID\u201019 infection appeared to have a shorter time to complete recovery. Complete recovery of FNP in non\u2010GBS patients was achieved in over two thirds of patients within almost 20\u2009days with and without treatments. Previous studies on the natural history of Bell’s palsy have suggested that approximately 85% of patients begin to experience some recovery of their FNP within the first 3\u2009weeks. 71 <\/a>However, complete recovery of Bell’s palsy with steroid treatment is typically seen in 3\u20139\u2009months and our study was limited in terms of follow up duration. 78 <\/a>In our non\u2010GBS cohort, complete recovery was achieved in the majority (62%) within the first 2\u2009months.<\/p>\n\n\n\n

Although our study did not identify any significant predictors of FNP outcomes related to treatment for COVID\u201019 patients, this is likely due to the limited sample size, and is an area for future research.<\/p>\n\n\n\n

Etiology<\/h3>\n\n\n\n

Infectious etiology of FNP has a broad differential. Presumed culprits include HSV, VZV, EBV, and Borrelia burgdorferi. With the advent of COVID\u201019, our results suggest that the etiology of FNP in non\u2010GBS COVID\u201019 patients is potentially novel.<\/p>\n\n\n\n

COVID\u201019 has been hypothesized to cause neurologic damage by two distinct mechanisms: (1) dissemination to the central nervous system by hematogenous spread or trans\u2010neuronally via cranial nerves causing direct neuronal damage due to viral neurotropism and (2) neuronal damage secondary to an abnormal immune\u2010mediated response. 6 <\/a>, 79 <\/a>The first is thought to be responsible for cranial nerve manifestations (e.g., hypogeusia, hyposmia, headache, and vertigo), whereas the latter mechanism is believed to result in severe complications and contribute to the development of dysimmune neuropathies like GBS. 13 <\/a>, 80<\/a><\/p>\n\n\n\n

Our findings indicate that among the non\u2010GBS patients, a suggestion can be made of an association between COVID\u201019 and a clinical manifestation of FNP, although no causation can be assumed. Although the acute onset and age distribution of the non\u2010GBS patients present similarly to Bell’s palsy, the differences in clinical presentations and outcomes should be considered. The non\u2010GBS subgroup had a relatively shorter duration to complete recovery and a higher proportion of bilateral FNP compared to Bell’s palsy patients. 69 <\/a>, 78<\/a><\/p>\n\n\n\n

This study is not without limitations. Firstly, a full infectious work\u2010up to rule out other potential infectious causes of FNP was done in only 41% patients, although it was non\u2010contributory except for one patient who also had an active concurrent EBV infection. Secondly, there was variability in the length of follow\u2010up with the majority being 60\u2009days or less and thus long\u2010term outcomes data are limited. Since the full recovery of Bell’s palsy typically occurs within a year, this limitation may be underestimating the recovery in our patients. Furthermore, we did not discuss treatment specific outcomes as we were unable to control for multiple patient specific variables and concurrent treatments. Another important limitation is that case reports and case series are more likely to report severe manifestations of COVID\u201019. Therefore, the patients included in our study may not represent the complete spectrum of FNP associated COVID\u201019, and instead could underestimate the true prevalence of mild, undifferentiated, or undiagnosed cases. Additionally, the onset of FNP was determined relative to patient awareness of related COVID\u201019 symptom(s) which may have been non\u2010specific and may not have been accurately reported. Finally, since the completion of our literature search in November 2021, subsequent omicron and delta variants may not have been adequately represented in our results. Despite these limitations, this study is the first systematic review on patients with COVID\u201019 and FNP and may help advance knowledge and guide management of these patients.<\/p>\n\n\n\n

Go to:<\/a><\/p>\n\n\n\n

CONCLUSION<\/h2>\n\n\n\n

Although COVID\u201019 symptoms are predominantly respiratory, emerging evidence has highlighted various neurologic manifestations associated with COVID\u201019 infections. Our study highlights and delineates the presentations of FNP in the context of COVID\u201019 for systemic conditions such as GBS as well as an isolated FNP. Systemic and isolated cases of FNP during COVID\u201019 infections present and progress differently. Additionally, the clinical course of isolated FNP associated with COVID\u201019 appears to differ from typical Bell’s palsy presentation and prognosis. This suggests that patients with COVID\u201019 may have an atypical presentation of Bell’s palsy with a more severe initial presentation and a relatively better prognosis with higher propensity for complete recovery. This review suggests COVID\u201019 infection may be associated with the development of a unique clinical manifestation of FNP. There is some literature associating FNP with COVID\u201019, although a causal association cannot be definitively assumed. Our study may help future practitioners in identifying FNP as a possible sequela of COVID\u201019 infection that may aid in the management of these patients.<\/p>\n\n\n\n

Go to:<\/a><\/p>\n\n\n\n

Supporting information<\/h2>\n\n\n\n

Table S1.<\/strong> Database Search Algorithm.<\/p>\n\n\n\n

Table S2A.<\/strong> Case Reports Risk of Bias Assessment.<\/p>\n\n\n\n

Table S2B.<\/strong> Case Series Risk of Bias Assessment.<\/p>\n\n\n\n

Table S3.<\/strong> Study Demographics<\/p>\n\n\n\n

Click here for additional data file.<\/a>(93K, docx)<\/sup><\/p>\n\n\n\n

REFERENCES<\/h2>\n\n\n\n

1. Mov\u00e9rare T, Lohmander A, Hultcrantz M, Sj\u00f6green L. Peripheral facial palsy: speech, communication and oral motor function. Eur Ann Otorhinolaryngol Head Neck Dis<\/em>. 2017;134(1):27\u201031. [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

2. Lorch M, Teach SJ. Facial nerve palsy: etiology and approach to diagnosis and treatment. Pediatr Emerg Care<\/em>. 2010;26(10):763\u2010769. [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

3. Karalok ZS, Taskin BD, Ozturk Z, Gurkas E, Koc TB, Guven A. Childhood peripheral facial palsy. Childs Nerv Syst<\/em>. 2018;34(5):911\u2010917. 10.1007\/s00381-018-3742-9. [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

4. Jeon Y, Lee H. Ramsay Hunt syndrome. J Dent Anesth Pain Med<\/em>. 2018;18(6):333\u2010337. [PMC free article<\/a>] [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

5. Goh Y, Beh DLL, Makmur A, Somani J, Chan ACY. Pearls & Oy\u2010sters: facial nerve palsy in COVID\u201019 infection. Neurology<\/em>. 2020;95(8):364\u2010367. [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

6. Lima MA, Silva MTT, Soares CN, et al. Peripheral facial nerve palsy associated with COVID\u201019. J Neurovirol<\/em>. 2020;26(6):941\u2010944. [PMC free article<\/a>] [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

7. Figueiredo R, Falc\u00e3o V, Pinto MJ, Ramalho C. Peripheral facial paralysis as presenting symptom of COVID\u201019 in a pregnant woman. BMJ Case Rep<\/em>. 2020;13(8):e237146. [PMC free article<\/a>] [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

8. Brisca G, Garbarino F, Carta S, et al. Increased childhood peripheral facial palsy in the emergency department during COVID\u201019 pandemic. Pediatr Emerg Care<\/em>. 2020;36(10):E595\u2010E596. [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

9. Mackenzie N, Lopez\u2010Coronel E, Dau A, et al. Concomitant Guillain\u2010Barre syndrome with COVID\u201019: a case report. BMC Neurol<\/em>. 2021;21(1):135. [PMC free article<\/a>] [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

10. Ottaviani D, Boso F, Tranquillini E, et al. Early Guillain\u2010Barr\u00e9 syndrome in coronavirus disease 2019 (COVID\u201019): a case report from an Italian COVID\u2010hospital. Neurol Sci<\/em>. 2020;41(6):1351\u20101354. [PMC free article<\/a>] [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

11. Bsales S, Olson B, Gaur S, et al. Bell’s palsy associated with SARS\u2010CoV\u20102 infection in a 2\u2010year\u2010old child. J Pediatr Neurol<\/em>. 2021;19(6):440\u2010442. [Google Scholar<\/a>]<\/p>\n\n\n\n

12. Jasti AK, Selmi C, Sarmiento\u2010Monroy JC, Vega DA, Anaya JM, Gershwin ME. Guillain\u2010Barr\u00e9 syndrome: causes, immunopathogenic mechanisms and treatment. Expert Rev Clin Immunol<\/em>. 2016;12(11):1175\u20101189. [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

13. Abu\u2010Rumeileh S, Abdelhak A, Foschi M, Tumani H, Otto M. Guillain\u2013Barr\u00e9 syndrome spectrum associated with COVID\u201019: an up\u2010to\u2010date systematic review of 73 cases. J Neurol<\/em>. 2021;268(4):1133\u20101170. [PMC free article<\/a>] [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

14. Walling AD, Dickson G. Guillain\u2010Barre syndrome. Am Fam Physician<\/em>. 2013;87(3):191\u2010197. [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

15. House JW, Brackmann DE. Facial nerve grading system. Otolaryngol Head Neck Surg<\/em>. 1985;93(2):146\u2010147. [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

16. Cabrera Muras A, Carmona\u2010Abell\u00e1n MM, Coll\u00eda Fern\u00e1ndez A, Uterga Valiente JM, Ant\u00f3n M\u00e9ndez L, Garc\u00eda\u2010Monc\u00f3 JC. Bilateral facial nerve palsy associated with COVID\u201019 and Epstein\u2010Barr virus co\u2010infection. Eur J Neurol<\/em>. 2021;28(1):358\u2010360. [PMC free article<\/a>] [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

17. Chan JL, Ebadi H, Sarna JR. Guillain\u2010Barr\u00e9 syndrome with facial diplegia related to SARS\u2010CoV\u20102 infection. Can J Neurol Sci<\/em>. 2020;47(6):1\u2010854. [PMC free article<\/a>] [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

18. Chan M, Han SC, Kelly S, Tamimi M, Giglio B, Lewis A. A case series of Guillain\u2010Barr\u00e9 syndrome after COVID\u201019 infection in New York. Neurol Clin Pract<\/em>. 2021;11(4):e576\u2010e578. [PMC free article<\/a>] [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

19. Chaumont H, San\u2010Galli A, Martino F, et al. Mixed central and peripheral nervous system disorders in severe SARS\u2010CoV\u20102 infection. J Neurol<\/em>. 2020;267(11):1\u20103127. [PMC free article<\/a>] [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

20. Corr\u00eaa DG, Hygino da Cruz LC, Lopes FCR, et al. Magnetic resonance imaging features of COVID\u201019\u2010related cranial nerve lesions. J Neurovirol<\/em>. 2021;27(1):1. [PMC free article<\/a>] [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

21. Dahl EH, Mosevoll KA, Cramariuc D, Vedeler CA, Blomberg B. COVID\u201019 myocarditis and postinfection Bell’s palsy. BMJ Case Rep<\/em>. 2021;14(1):e240095. [PMC free article<\/a>] [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

22. de Freitas Ribeiro BN, Marchiori E. Facial palsy as a neurological complication of SARS\u2010CoV\u20102. Arq Neuropsiquiatr<\/em>. 2020;78(10):667. [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

23. Derollez C, Alberto T, Leroi I, Mackowiak MA, Chen Y. Facial nerve palsy: an atypical clinical manifestation of COVID\u201019 infection in a family cluster. Eur J Neurol<\/em>. 2020;27(12):2670\u20102672. [PMC free article<\/a>] [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

24. Doo FX, Kassim G, Lefton DR, Patterson S, Pham H, Belani P. Rare presentations of COVID\u201019: PRES\u2010like leukoencephalopathy and carotid thrombosis. Clin Imaging<\/em>. 2021;69:94\u2010101. [PMC free article<\/a>] [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

25. Gogia B, Gil Guevara A, Rai PK, Fang X. A case of COVID\u201019 with multiple cranial neuropathies. Int J Neurosci<\/em>. 2020;1\u20103. 10.1080\/00207454.2020.1869001. [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

26. Gonz\u00e1lez\u2010Castro A, Rodr\u00edguez ER, Arnaiz F, Pargada DF. Par\u00e1lisis facial perif\u00e9rica en pacientes con SARS\u2010CoV\u20102 en dec\u00fabito prono. Rev Neurol<\/em>. 2021;72(8):296\u2010297. [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

27. Guilmot A, Maldonado Slootjes S, Sellimi A, et al. Immune\u2010mediated neurological syndromes in SARS\u2010CoV\u20102\u2010infected patients. J Neurol<\/em>. 2021;268(3):751\u2010757. [PMC free article<\/a>] [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

28. Homma Y, Watanabe M, Inoue K, Moritaka T. Coronavirus disease\u201019 pneumonia with facial nerve palsy and olfactory disturbance. Intern Med<\/em>. 2020;59(14):1773\u20101775. [PMC free article<\/a>] [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

29. Hutchins KL, Jansen JH, Comer AD, et al. COVID\u201019\u2010associated bifacial weakness with paresthesia subtype of Guillain\u2010Barr\u00e9 syndrome. AJNR Am J Neuroradiol<\/em>. 2020;41(9):1707\u20101711. [PMC free article<\/a>] [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

30. Juliao Caama\u00f1o DS, Alonso Beato R. Facial diplegia, a possible atypical variant of Guillain\u2010Barr\u00e9 syndrome as a rare neurological complication of SARS\u2010CoV\u20102. J Clin Neurosci<\/em>. 2020;77:230\u2010232. [PMC free article<\/a>] [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

31. Kaplan AC. Noteworthy neurological manifestations associated with COVID\u201019 infection. Cureus<\/em>. 2021;13(4):e14391. [PMC free article<\/a>] [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

32. Khaja M, Roa Gomez GP, Santana Y, et al. A 44\u2010year\u2010old Hispanic man with loss of taste and bilateral facial weakness diagnosed with Guillain\u2010Barr\u00e9 syndrome and Bell’s palsy associated with SARS\u2010CoV\u20102 infection treated with intravenous immunoglobulin. Am J Case Rep<\/em>. 2020;21:e927956\u2010e927951. [PMC free article<\/a>] [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

33. Kilinc D, van de Pasch S, Doets AY, Jacobs BC, van Vliet J, Garssen MPJ. Guillain\u2013Barr\u00e9 syndrome after SARS\u2010CoV\u20102 infection. Eur J Neurol<\/em>. 2020;27(9):1757\u20101758. [PMC free article<\/a>] [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

34. Kumar V, Narayanan P, Shetty S, Mohammed AP. Lower motor neuron facial palsy in a postnatal mother with COVID\u201019. BMJ Case Rep<\/em>. 2021;14(3):e240267. [PMC free article<\/a>] [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

35. Lascano AM, Epiney JB, Coen M, et al. SARS\u2010CoV\u20102 and Guillain\u2010Barr\u00e9 syndrome: AIDP variant with a favourable outcome. Eur J Neurol<\/em>. 2020;27(9):1751\u20101753. [PMC free article<\/a>] [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

36. Manganotti P, Bellavita G, D’Acunto L, et al. Clinical neurophysiology and cerebrospinal liquor analysis to detect Guillain\u2010Barr\u00e9 syndrome and polyneuritis cranialis in COVID\u201019 patients: a case series. J Med Virol<\/em>. 2021;93(2):766\u2010774. [PMC free article<\/a>] [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

37. McDonnell EP, Altomare NJ, Parekh YH, et al. COVID\u201019 as a trigger of recurrent Guillain\u2013Barr\u00e9 syndrome. Pathogens<\/em>. 2020;9(11):1\u20109. [PMC free article<\/a>] [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

38. Mehta S, Mackinnon D, Gupta S. Severe acute respiratory syndrome coronavirus 2 as an atypical cause of Bell’s palsy in a patient experiencing homelessness. CJEM<\/em>. 2020;22(5):1\u2010610. [PMC free article<\/a>] [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

39. Nanda S, Handa R, Prasad A, et al. Covid\u201019 associated Guillain\u2010Barre syndrome: contrasting tale of four patients from a tertiary care centre in India. Am J Emerg Med<\/em>. 2021;39:125\u2010128. [PMC free article<\/a>] [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

40. Neo WL, Ng JCF, Iyer NG. The great pretender\u2014Bell’s palsy secondary to SARS\u2010CoV\u20102? Clin Case Rep<\/em>. 2021;9(3):1175\u20101177. [PMC free article<\/a>] [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

41. Ochoa\u2010Fern\u00e1ndez EG, V\u00edllora\u2010Morcillo N, Taboas\u2010Pereira A. Par\u00e1lisis facial perif\u00e9rica en un paciente pedi\u00e1trico sin factores de riesgo en el contexto de infecci\u00f3n por SARS\u2010CoV\u20102. Rev Neurol<\/em>. 2021;72(5):177\u2010178. [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

42. Oke IO, Oladunjoye OO, Oladunjoye AO, Paudel A, Zimmerman R. Bell’s palsy as a late neurologic manifestation of COVID\u201019 infection. Cureus<\/em>. 2021;13(3):e13881. [PMC free article<\/a>] [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

43. Paybast S, Gorji R, Mavandadi S. Guillain\u2010Barr\u00e9 syndrome as a neurological complication of novel COVID\u201019 infection: a case report and review of the literature. Neurologist<\/em>. 2020;25(4):101\u2010103. [PMC free article<\/a>] [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

44. Pelea T, Reuter U, Schmidt C, Laubinger R, Siegmund R, Walther BW. SARS\u2010CoV\u20102 associated Guillain\u2013Barr\u00e9 syndrome. J Neurol<\/em>. 2021;268(4):1191\u20101194. [PMC free article<\/a>] [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

45. Pfefferkorn T, Dabitz R, von Wernitz\u2010Keibel T, Aufenanger J, Nowak\u2010Machen M, Janssen H. Acute polyradiculoneuritis with locked\u2010in syndrome in a patient with Covid\u201019. J Neurol<\/em>. 2020;267(7):1\u20101884. [PMC free article<\/a>] [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

46. Pinna P, Grewal P, Hall JP, et al. Neurological manifestations and COVID\u201019: experiences from a tertiary care center at the frontline. J Neurol Sci<\/em>. 2020;415:116969. [PMC free article<\/a>] [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

47. Rana S, Lima AA, Chandra R, et al. Novel coronavirus (COVID\u201019)\u2010associated Guillain\u2013Barr\u00e9 syndrome: case report. J Clin Neuromuscul Dis<\/em>. 2020;21(4):240\u2010242. [PMC free article<\/a>] [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

48. Reyes\u2010Bueno JA, Garc\u00eda\u2010Trujillo L, Urbaneja P, et al. Miller\u2010Fisher syndrome after SARS\u2010CoV\u20102 infection. Eur J Neurol<\/em>. 2020;27(9):1759\u20101761. [PMC free article<\/a>] [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

49. Saberi H, Tanha RR, Derakhshanrad N, Soltaninejad MJ. Acute presentation of third ventricular cavernous malformation following COVID\u201019 infection in a pregnant woman: a case report. Neurochirurgie<\/em>. 2021;68(2):228\u2010231. [PMC free article<\/a>] [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

50. Sancho\u2010Salda\u00f1a A, Lambea\u2010Gil \u00c1, Capablo Liesa JL, et al. Guillain\u2013Barr\u00e9 syndrome associated with leptomeningeal enhancement following SARS\u2010CoV\u20102 infection. Clin Med<\/em>. 2020;20(4):e93\u2010e94. [PMC free article<\/a>] [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

51. Sedaghat Z, Karimi N. Guillain Barre syndrome associated with COVID\u201019 infection: a case report. J Clin Neurosci<\/em>. 2020;76:233\u2010235. [PMC free article<\/a>] [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

52. Tard C, Maurage CA, de Paula AM, et al. Anti\u2010pan\u2010neurofascin IgM in COVID\u201019\u2010related Guillain\u2010Barr\u00e9 syndrome: evidence for a nodo\u2010paranodopathy. Neurophysiol Clin<\/em>. 2020;50(5):397\u2010399. [PMC free article<\/a>] [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

53. Ta\u015fl\u0131dere B, Mehmetaj L, \u00d6zcan AB, G\u00fclen B, Ta\u015fl\u0131dere N. Melkersson\u2010Rosenthal syndrome induced by COVID\u201019. Am J Emerg Med<\/em>. 2021;41:262.e5\u2010262.e7. [PMC free article<\/a>] [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

54. Tekin AB, Zanapalioglu U, Gulmez S, Akarsu I, Yassa M, Tug N. Guillain Barre syndrome following delivery in a pregnant woman infected with SARS\u2010CoV\u20102. J Clin Neurosci<\/em>. 2021;86:190\u2010192. [PMC free article<\/a>] [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

55. Theophanous C, Santoro JD, Itani R. Bell’s palsy in a pediatric patient with hyper IgM syndrome and severe acute respiratory syndrome coronavirus 2 (SARS\u2010CoV\u20102). Brain Dev<\/em>. 2021;43(2):357\u2010359. [PMC free article<\/a>] [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

56. Tiet MY, Alshaikh N. Guillain\u2010Barr\u00e9 syndrome associated with COVID\u201019 infection: a case from the UK. BMJ Case Rep<\/em>. 2020;13(7):e236536. [PMC free article<\/a>] [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

57. Toscano G, Palmerini F, Ravaglia S, et al. Guillain\u2010Barr\u00e9 syndrome associated with SARS\u2010CoV\u20102. N Engl J Med<\/em>. 2020;382(26):2574\u20102576. [PMC free article<\/a>] [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

58. Wong PF, Craik S, Newman P, et al. Lessons of the month 1: a case of rhombencephalitis as a rare complication of acute COVID\u201019 infection. Clin Med (Northfield Il)<\/em>. 2020;20(3):293\u2010294. [PMC free article<\/a>] [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

59. Zain S, Petropoulou K, Mirchia K, Hussien A, Mirchia K. COVID\u201019 as a rare cause of facial nerve neuritis in a pediatric patient. Radiol Case Rep<\/em>. 2021;16(6):1400\u20101404. [PMC free article<\/a>] [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

60. Abolmaali M, Heidari M, Zeinali M, et al. Guillain\u2013Barr\u00e9 syndrome as a parainfectious manifestation of SARS\u2010CoV\u20102 infection: a case series. J Clin Neurosci<\/em>. 2021;83:119\u2010122. [PMC free article<\/a>] [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

61. Almutairi A, Bin Abdulqader S, Alhameed M, Alit S, Alosaimi B. Guillain\u2010Barr\u00e9 syndrome following COVID\u201019: a case report. J Res Med Dent Sci<\/em>. 2021;9(3):7\u201010. [Google Scholar<\/a>]<\/p>\n\n\n\n

62. Bastola A, Sah R, Nepal G, et al. Bell’s palsy as a possible neurological complication of COVID\u201019: a case report. Clin Case Rep<\/em>. 2021;9(2):747\u2010750. [PMC free article<\/a>] [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

63. Bigaut K, Mallaret M, Baloglu S, et al. Guillain\u2010Barr\u00e9 syndrome related to SARS\u2010CoV\u20102 infection. Neurol Neuroimmunol Neuroinflamm<\/em>. 2020;7(5):785. [PMC free article<\/a>] [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

64. Kanerva M, Jones S, Pitkaranta A. Ramsay Hunt syndrome: characteristics and patient self\u2010assessed long\u2010term facial palsy outcome. Eur Arch Otorhinolaryngol<\/em>. 2020;277(4):1235\u20101245. [PMC free article<\/a>] [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

65. Aizawa H, Ohtani F, Futura Y, Sawa H, Fukuda S. Variable patterns of varicella\u2010zoster virus reactivation in Ramsay Hunt syndrome. J Med Virol<\/em>. 2004;74(2):355\u2010360. [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

66. Adour KK, Byl FM, Hilsinger RL, Kahn ZM, Sheldon MI. The true nature of Bell’s palsy: analysis of 1,000 consecutive patients. Laryngoscope<\/em>. 1978;88(5):787\u2010801. [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

67. Adour KK, Swanson PJ. Facial paralysis in 403 consecutive patients: emphasis on treatment response in patients with Bell’s palsy. Trans Am Acad Ophthalmol Otolaryngol<\/em>. 1971;75(6):1284\u20101301. [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

68. Leibowitz U. Bell’s palsy\u2014two disease entities? Neurology<\/em>. 1966;16(11):1105\u20101109. [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

69. McGoveen FH. Bilateral Bell’s palsy. Laryngoscope<\/em>. 1965;75(7):1070\u20101080. [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

70. Van Den Berg B, Walgaard C, Drenthen J, Fokke C, Jacobs BC, Van Doorn PA. Guillain\u2010Barr\u00e9 syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol<\/em>. 2014;10(8):469\u2010482. [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

71. Eviston TJ, Croxson GR, Kennedy PGE, Hadlock T, Krishnan AV. Bell’s palsy: aetiology, clinical features and multidisciplinary care. J Neurol Neurosurg Psychiatry<\/em>. 2015;86(12):1356\u20101361. [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

72. Baugh RF, Basura GJ, Ishii LE, et al. Clinical practice guideline: Bell’s palsy. Otolaryngol Head Neck Surg<\/em>. 2013;149:S1\u2010S27. [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

73. Gronseth GS, Paduga R. Evidence\u2010based guideline update: steroids and antivirals for Bell palsy: report of the guideline development subcommittee of the American academy of neurology. Neurology<\/em>. 2012;79(22):2209\u20102213. [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

74. Tang IP, Lee SC, Shashinder S, Raman R. Outcome of patients presenting with idiopathic facial nerve paralysis (Bell’s palsy) in a tertiary centre \u2010 a five year experience. Med J Malaysia<\/em>. 2009;64(2):155\u2010158. [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

75. Da Costa Monsanto R, Bittencourt AG, Bobato Neto NJ, Beilke SCA, Lorenzetti FTM, Salomone R. Treatment and prognosis of facial palsy on Ramsay Hunt syndrome: results based on a review of the literature. Int Arch Otorhinolaryngol<\/em>. 2016;20(4):394\u2010400. [PMC free article<\/a>] [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

76. Rapha\u00ebl JC, Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain\u2010Barr\u00e9 syndrome. Cochrane Database Syst Rev<\/em>. 2012;7:CD001798. [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

77. Hughes RA, Swan AV, van Koningsveld R, van Doorn PA. Corticosteroids for Guillain\u2010Barr\u00e9 syndrome. Cochrane Database Syst Rev<\/em>. 2006;2:CD001446. [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

78. Sullivan FM, Swan IR, Donnan PT, et al. Early treatment with prednisolone or acyclovir in Bell’s palsy. Clin Otolaryngol<\/em>. 2007;32(6):460. [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

79. Costello F, Dalakas MC. Cranial neuropathies and COVID\u201019: neurotropism and autoimmunity. Neurology<\/em>. 2020;95(5):195\u2010196. [PubMed<\/a>] [Google Scholar<\/a>]<\/p>\n\n\n\n

80. Wang L, Shen Y, Li M, et al. Clinical manifestations and evidence of neurological involvement in 2019 novel coronavirus SARS\u2010CoV\u20102: a systematic review and meta\u2010analysis. J Neurol<\/em>. 2020;267(10):2777\u20102789. [PMC free article<\/a>] [PubMed<\/a>] [Google Scholar<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Authors: Amirpouyan Namavarian, MD, 1 Anas Eid, BMSc, 2 Hedyeh Ziai, MD, 1 Emily YiQin Cheng, BSc, 3 and Danny Enepekides, MD, MSc, FRCSC Laryngoscope. 2022 Aug 8 : 10.1002\/lary.30333. doi: 10.1002\/lary.30333 Abstract Objective Several cases of facial nerve paralysis (FNP) post\u2010COVID\u201019 […]<\/p>\n","protected":false},"author":2,"featured_media":5859,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[101,163,802,164,561],"tags":[],"class_list":["post-5848","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-covid-19","category-facial-nerve","category-facial-nerve-palsy","category-facial-nerve-paly","category-symptoms-covid-19"],"_links":{"self":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts\/5848","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=5848"}],"version-history":[{"count":0,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts\/5848\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/media\/5859"}],"wp:attachment":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=5848"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=5848"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=5848"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}